Faricimab, a bispecific antibody, simultaneously targets angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), and is utilized in research on diabetic macular edema (DME) [1].
CAS Number:
[1607793-29-2]
Target:
RG7716
* VAT and and shipping costs not included. Errors and price changes excepted
